Early Phase 1
N=20
The Influence of Testosterone on Experimental Pain Perception
Acute Pain
Bottom Line
View on ClinicalTrials.gov: NCT05781685 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Pain Tolerance — 224.20500; 224.92615 Seconds
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Testosterone (Drug); Placebo Syrup (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of New Mexico
- Primary completion
- Jul 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Tolerance |
224.20500; 224.92615 | — |
| SECONDARY Changes Testosterone Levels |
580.299600; 38.3972 | — |
| SECONDARY Changes Estradiol Levels |
-0.903160000000; 0.1801549999999 | — |
| SECONDARY Changes Progesterone Levels |
-423.63719; 29.381135 | — |
Summary
This trial examined how the administration of exogenous testosterone would influence pain tolerance and other endogenous steroids (i.e. estradiol and progesterone).
Eligibility Criteria
Inclusion Criteria
- Healthy college-aged females that are over the age of 18 and younger than 25 will be used for this study.
Exclusion Criteria
- The following criteria will exclude a participant from the study:
- Anyone that has a tree nut allergy.
- Women that are pregnant or may feel that they may be pregnant or breast-feeding.
- Anyone taking supplements that may influence their testosterone level.
- Anyone taking any kind of steroid that may increase their testosterone level.
- Anyone that smokes tobacco or uses smokeless tobacco.
- Anyone that reports any condition associated with nerve damage.
- Anyone that is using hormonal contraceptive.
- Anyone who was sick or unwell at the time of screening.
- Each participant completed a Testosterone Pre-Screen form. This form asked each participant individually whether they are taking any drugs or have any conditions that might be exacerbated by testosterone. This form was completed before they signed the consent form and each time they arrived in the lab for an experimental session.
Data sourced from ClinicalTrials.gov (NCT05781685). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.